GlassScriptPhysician profile
Marwan Obid
NPI 1518945625
$25,206.44
in general payments reported to CMS, 2019-2025
54 companies · $4,265 in 2025
The $4,265 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,358 · 2020: $3,369 · 2021: $3,176 · 2022: $3,311 · 2023: $3,187 · 2024: $3,541 · 2025: $4,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $143 · Consulting Fee: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,826.09 |
| Education | $142.81 |
| Consulting Fee | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,628.96 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $2,852.03 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Grifols USA, LLC | $1,803.05 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,730.10 | 2019-2025 | Ofev, Spiriva Respimat, Jardiance |
| Regeneron Healthcare Solutions, INC. | $1,369.67 | 2019-2025 | Dupixent |
| Novo Nordisk INC | $1,155.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Genzyme Corporation | $1,016.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $915.34 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $791.21 | 2019-2023 | Xarelto |
| Insmed, INC. | $691.28 | 2020-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $642.81 | 2019-2024 | Yupelri |
| Csl Behring | $600.35 | 2019-2025 | Hizentra, Andembry |
| Allergan, INC. | $503.11 | 2019-2020 | |
| Octapharma USA, INC. | $468.92 | 2021-2025 | Cutaquig, Octagam Immune Globulin (Human) |
| Jazz Pharmaceuticals INC. | $430.37 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marwan Obid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.